Theriva Begin Period Cash Flow from 2010 to 2025
| TOVX Stock | USD 1.46 0.09 6.57% |
Begin Period Cash Flow | First Reported 1993-03-31 | Previous Quarter 18.3 M | Current Value 16.7 M | Quarterly Volatility 16.6 M |
Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.19. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.
Theriva | Begin Period Cash Flow |
Latest Theriva Biologics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Theriva Biologics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Theriva Biologics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Theriva Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 22,916,493 | |
| Geometric Mean | 12,875,279 | |
| Coefficient Of Variation | 84.50 | |
| Mean Deviation | 15,286,178 | |
| Median | 17,525,000 | |
| Standard Deviation | 19,364,874 | |
| Sample Variance | 375T | |
| Range | 67.2M | |
| R-Value | 0.80 | |
| Mean Square Error | 146.7T | |
| R-Squared | 0.63 | |
| Significance | 0.0002 | |
| Slope | 3,240,701 | |
| Total Sum of Squares | 5625T |
Theriva Begin Period Cash Flow History
About Theriva Biologics Financial Statements
Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 48.2 M | 50.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.